文献速递肿瘤 PET/CT放射性药物与辐射防护

COVID-19疫苗接种后PET/CT表现的经验总结

Lessons Learned from Post-COVID-19 Vaccination PET/CT Studies.
PubMed 文献 · J Nucl Med · 2021-07-22

分析2021年1月1日至2月15日期间1018例常规PET/CT研究,收集疫苗接种日期与部位信息,视觉与半定量分析腋窝-颈部淋巴结肿大及手臂摄取并与免疫数据关联。接种后常见单侧腋窝淋巴结摄取增高,随时间强度下降;20%患者出现手臂注射部位与同侧腋窝淋巴结同时摄取增高的「双征」,双征对接种后淋巴结肿大的特异性与阳性预测值均为100%。

要点

  • 接种后常见单侧腋窝淋巴结PET摄取增高,强度随时间下降。
  • 20%接种患者出现手臂注射部位与同侧腋窝淋巴结同时摄取的「双征」。
  • 双征对接种后淋巴结肿大的特异性与阳性预测值均为100%,可避免误判。

核心结论

  • COVID-19疫苗接种常引起非特异性腋窝淋巴结PET示踪剂摄取增高。
  • 约五分之一研究人群的淋巴结肿大伴接种部位摄取增高,即双征。
  • 双征对接种后淋巴结肿大的特异性与阳性预测值均为100%,有助于避免PET/CT误判及不必要的进一步检查。

研究设计与样本

  • 分析2021年1月1日至2021年2月15日期间进行的1018例PET/CT研究。
  • 收集疫苗接种日期与部位信息,对腋窝-颈部淋巴结肿大及手臂摄取进行视觉与半定量分析并与免疫数据关联。

主要发现

  • 接种患者中66%观察到单侧腋窝淋巴结摄取增高,接种一次者中为55%,接种两次者中为69%。
  • 摄取强度随时间下降。
  • 腋窝淋巴结肿大的敏感性、特异性、阳性预测值、阴性预测值分别为55.4%、83.6%、86.7%、49.2%;双征分别为38.6%、100%、100%、66.1%。
  • 首次与第二次接种后分别未在10天和21天后观察到双征;未接种患者均无手臂摄取或双征。

关键数值与推荐

  • 腋窝淋巴结肿大对接种后状态的敏感性55.4%、特异性83.6%、阳性预测值86.7%、阴性预测值49.2%。
  • 双征对接种后状态的敏感性38.6%、特异性100%、阳性预测值100%、阴性预测值66.1%。
  • 首次接种后10天内、第二次接种后21天内可观察到双征。

临床怎么用

  • 读片时结合疫苗接种史(日期与部位)判断腋窝淋巴结摄取增高及手臂摄取。
  • 识别双征(手臂注射部位与同侧腋窝淋巴结同时摄取增高)可高度提示接种后改变,避免误判为转移或进一步不必要的检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination against coronavirus 2019 (COVID-19) has created new challenges. Lymphadenopathy with increased uptake in patients undergoing PET/CT may mislead to unnecessary further evaluation. We have analyzed routinely performed PET/CT studies after Pfizer-BioNTech vaccination to familiarize ourselves with the PET/CT appearance of various PET tracers and to prevent the consequences of misinterpretation. Methods: We analyzed 1,018 PET/CT studies performed between January 1, 2021, and February 15, 2021. Information about the dates and sites of vaccination was collected. Visual and semiquantitative analysis of axillary-neck lymphadenopathy and arm uptake was correlated with immunization data. Results: Increased uptake in axillary lymphadenopathy was observed unilaterally in 66% of vaccinated patients, in 55% of patients vaccinated once, and in 69% of those vaccinated twice. The intensity of uptake decreased over time. Fifty-four of 274 patients (20%) had simultaneous increased activity in the posterior arm and ipsilateral axillary lymphadenopathy (double sign [DS]). The sensitivity, specificity, positive predictive value, and negative predictive value were 55.4%, 83.6%, 86.7%, 49.2%, respectively, for axillary lymphadenopathy and 38.6%, 100%, 100%, and 66.1%, respectively, for DS. No DS was observed later than 10 and 21 d after the first and the second vaccinations, respectively. None of the nonvaccinated patients had arm uptake or DS. Conclusion: Vaccination against COVID-19 frequently causes nonspecific axillary lymphadenopathy with increased PET tracer activity. In one fifth of our study population, this lymphadenopathy was associated with increased uptake at the vaccination site, DS. DS was 100% specific, with a 100% positive predictive value for postvaccination lymphadenopathy, hence enabling avoidance of misinterpretation of PET/CT studies and further unnecessary evaluation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Orevi M, Chicheportiche A, Ben Haim S, et al. Lessons Learned from Post-COVID-19 Vaccination PET/CT Studies. J Nucl Med. 2021. PMID: 34301777. doi:10.2967/jnumed.121.262348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。